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1. INTRODUCTION 
1.1 MICROENCAPSULATION 
 Microencapsulation is a rapidly expanding technology. It is a means of applying 
relatively thin coatings to small particles of solids or droplets of liquids and dispersions. 
Microencapsulation is arbitrarily differentiated from macro coating techniques in that the 
former involves the coating of particles ranging dimensionally from several thnth of a 
micron to 5000 microns in size. 
 Microencapsulation provides the means of converting liquids to solids, of altering 
colloidal and surface properties, of providing environmental protection, and of 
controlling the release characteristics or availability of coated materials. 
 Microencapsulation is a process whereby small discrete solid particles or small 
liquid droplets are surrounded or enclosed, by an intact shell. Two major classes of 
microencapsulation methods have evolved i.e. chemical and physical. 
 The first class of encapsulation method involves polymerization during the 
process of preparing the microcapsules. The second type involves the controlled 
precipitation of a polymeric solution where in physical changes usually occur. 
Microencapsulation Process 
Basic microencapsulation processes can be divided into chemical and mechanical. 
 Chemical Processes involved  
• Complex coacervation 
• Polymer-polymer compatibility 
• Interfacial polymerization in liquid media 
• In-situ polymerization 
• In-liquid drying 
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• Thermal and ionic gelation in liquid media 
 Mechanical Processes involved  
• Spray drying 
• Spray coating 
• Fluidized bed coating 
• Electrostatic deposition 
• Centrifugal extrusion 
• Spinning disk or rotational suspension separation 
• Polymerization at liquid-gas or solid-gas interface 
• Pressure extraction or spraying into solvent extraction bath. 
    Ideal Characteristics of Drug for Microencapsulation 
• The drug or the protein should not be adversely by the process 
• Reproducibility of the release profile and the method 
•  No Stability Problem 
•  Particle size requirement 
The lower the molecular weight, faster and complete is the absorption 
of the drug. The drugs having size 150-600 Daltons they can easily diffuse 
through the membrane. 
• There should be no toxic product associated with the final product 
• Therapeutic range 
A candidate drug for controlled delivery system should have a therapeutic 
range wide enough such that variations in the release rate do not result in a 
concentration beyond this level. 
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• Therapeutic index 
The ratio of maximum safe concentration to the minimum effective 
concentration of drug is called as therapeutic index. It is necessary because such 
drugs have toxic concentration nearer to their therapeutic range. 
• Elimination half life 
Drugs with t1/2 in the range of 2 to 4 hours are good candidates. 
Many drugs have been microencapsulated to reduce the gastric and other 
gastrointestinal tract irritation. The local irritation and release properties of a 
number of topically applied products can be altered by microencapsulation. This 
process is also used to mask the taste of bitter drugs. 
Microencapsulation has been widely employed in the design of controlled 
release and sustained release dosage forms. It is the most recent addition to oral 
prolonged release mechanisms.  
Table No. 1 
Microencapsulation Processes & their Applicability 
Microencapsulation 
process 
Applicable core material Approximate particle 
size 
Air suspension Solids 35-5000 
Coacervation-phase 
separation 
Solids & liquids 2-5000 
Multiorifice centrifugal Solids & liquids 1-5000 
Pan coating Solids 600-5000 
Solvent evaporation Solids & liquids 5-5000 
Spray drying and 
congealing 
Solids & liquids 600 
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 1.4.1. Methods of Preparation of Floating Microspheres 
Floating Microspheres can be prepared using any of the following techniques. 
(a) Solvent Evaporation 
It is the most extensively used method of microencapsulation, first described 
by (Ogawa et al.) a buffered or plain aqueous solution of the drug (may contain a 
viscosity building or stabilizing agent) is added to an organic phase consisting of the 
polymer solution in solvents like dichloromethane (or ethyl acetate or chloroform) with 
vigorous stirring to form the primary water containing an emulsifier like PVA or PVP to 
form the multiple emulsions (w/o/w). The double emulsion, so formed, is then subjected 
to stirring until most of the organic solvent evaporates, leaving solid microspheres. The 
Microspheres can then be washed, centrifuged and lyophilize to obtain the free flowing 
and dried microspheres. 
(b) Emulsion Polymerisation 
This method was first used by (Mathiowitz and Langer) to prepare 
microspheres of polyanhydride copolymer of poly [bis (p-carboxy phenoxy) propane 
anhydride] with sebacic acid. In this method, the polymer is first melted and then mixed 
with solid particles of the drug that have been sieved to less than 50 µm. The mixture is 
suspended in a non-miscible solvent (like silicone oil), continuously stirred, and heated to 
5ºC above the melting point of the polymer. Once the emulsion is stabilized, it is cooled 
until the polymer particle solidify. The resulting microspheres are washed by decantation 
with petroleum ether. 
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(c) Solvent Removal 
It is a non-aqueous method of microencapsulation, particularly suitable for 
water labile polymers such as the ploy anhydrides. In this method, drug is dispersed or 
dissolved in a solution of the selected polymer in a volatile organic solvent like 
methylene chloride. After pouring the polymer solution into silicone oil, petroleum ether 
is added and stirred until solvent is extracted into the oil solution. The resulting 
Microspheres can then be dried in vaccum  (Mathiowitz and Langer) 
(d) Spray Drying 
In this process, the drug may be dissolved or dispersed in the polymer solution 
and spray dried. The quality of spray-dried microspheres can be improved by the addition 
of plasticizers, e.g. citric acid, which promote polymer coalescence on the drug particles 
and hence promote the formation of spherical and smooth surfaced microspheres. The 
size of microspheres can be controlled by the rate of spraying, the feed rate of polymer 
drug solution, nozzle size, and the drying temperature. This method of micro 
encapsulation is particularly less dependent on the solubility characteristics of the drug 
and polymer and is simple, reproducible, and easy to scale up (Mathiowitz and Langer)
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1.2. Classification of GRDDS 
• Floating DDS (FDDS), with low density providing sufficient buoyancy to float 
over the gastric contents. 
• Bioadhesive systems, enabling the localized retention of the system in the 
stomach. 
• Swelling and expanding systems, preventing transit from the gastric sphincter. 
• High density system, remaining in the stomach for longer period of time by 
sedimenting to the folds of stomach. 
• Superporous hydrogels 
• Modified-shaped system 
1.2.1.  Floating Drug Delivery Systems 
The concept of FDDS was described in the literature as early as 1962. FDDS have 
a bulk density less than gastric fluids and so remain buoyant in the stomach without 
affecting the gastric emptying rate for a prolonged period of time. While the system is 
floating on the gastric contents the drug is released slowly at the desired rate from the 
system. This results in an increased GRT and a better control of fluctuations in plasma 
drug concentration. 
 
Figure 1. Mechanism of floating system. 
Formulation of this device must comply with the following criteria 
1) It must have sufficient structure to form a cohesive get barrier. 
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2) It must maintain an overall specific gravity lower than that of gastric contents  
      (1.004-1.010).  
3) It should dissolve slowly enough to serve as a drug reservoir.  
1.2.2. Types of floating drug delivery systems 
Based on the mechanism of buoyancy and two distinctly different technologies 
have been utilized in the development of FDDS. 
1) Non- Effervescent FDDS 
2) Effervescent FDDS  
1) Non-Effervescent FDDS 
The Non-effervescent FDDS is based on mechanism of swelling of polymer or 
bioadhesion to mucosal layer in GI tract. The most commonly used excipients in non-
effervescent FDDS are gel forming or highly swellable cellulose type hydrocolloids, 
hydrophilic gums, polysaccharides and matrix forming materials such as polycarbonate, 
polyacrylate, polymethacrylate, polystyrene as well as bioadhesive polymers such as 
Chitosan and carbopol. 
Working Principle of Non- Effervescent Type of FDDS 
Capsule/tablet contains a mixture of drug and hydrocolloids. Upon contact with 
gastric fluid, the mixture swells and forms a gelatinous barrier thereby remaining buoyant 
in the gastric juice for an extended period of time. 
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Figure 2. Working Principle of Non-Effervescent Type of FDDS 
The various types of this system are as: 
A. Single Layer Floating Tablets 
They are formulated by intimate mixing of drug with a gel-forming hydrocolloid, 
which swells in contact with gastric fluid and maintains bulk density of less than unity.  
They are formulated by intimate mixing of drug with low-density enteric 
materials such as  HPMC. 
B. Bi-layer Floating Tablets  
A bi-layer tablet contain two layer one immediate release layer which releases 
initial dose from system while the another sustained release layer absorbs gastric fluid, 
forming an impermeable colloidal gel barrier on its surface, and maintain a bulk density 
of less than unity and thereby it remains buoyant in the stomach (Oth et al., 1992). 
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C.  Alginate Beads  
Multi-unit floating dosage forms were developed from freeze-dried calcium 
alginate. Spherical beads of approximately 2.5 mm diameter can be prepared by dropping 
sodium alginate solution into aqueous solution of calcium chloride, causing precipitation 
of calcium alginate leading to formation of porous system, which can maintain a floating 
force for over 12 hours. When compared with solid beads, which gave a short residence 
time of 1 hour, and these floating beads gave a prolonged residence time of more than 5.5 
hours (katayama et al., 1999). 
D.  Hollow Microspheres  
Hollow microspheres (microballoons), loaded with drug in their outer polymer 
shells are prepared by a novel emulsion-solvent diffusion method. The ethanol: 
dichloromethane solution of the drug and an enteric acrylic polymer is poured into an 
agitated aqueous solution of PVA that is thermally controlled at 400C. The gas phase 
generated in dispersed polymer droplet by evaporation of dichloromethane forms an 
internal cavity in microsphere of polymer with drug. The microballoons float 
continuously over the surface of acidic dissolution media containing surfactant for more 
than 12 hours in vitro (Kawashima, 1992). 
2) Effervescent System 
Effervescent systems include use of gas generating agents, carbonates (ex. 
Sodium bicarbonate) and other organic acid (e.g. citric acid and tartaric acid) present in 
the formulation to produce carbon dioxide (CO2) gas, thus reducing the density of the 
system and making it float on the gastric fluid. An alternative is the incorporation of 
matrix containing portion of liquid, which produce gas that evaporates at body 
temperature. 
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These effervescent systems further classified into two types. 
1. Gas generating systems 
2. Volatile Liquid/Vacuum Containing Systems 
1.   Gas Generating Systems  
A. Tablets 
Floating bilayer tablets with controlled release for furosemide were developed by 
Ozdemir et al., 2000. The low solubility of the drug could be enhanced by using the 
kneading method, preparing a solid dispersion with β cyclodextrin mixed in a 1:1 ratio 
(Singh and Brahma, 2000). One layer contained the polymers HPMC K4M, HPMC 
K100M and CMC (for the control of the drug delivery) and the drug. The second layer 
contained the effervescent mixture of sodium bicarbonate and citric acid. The in vitro 
floating studies revealed that the lesser the compression force the shorter is the time of 
onset of floating, i.e., when the tablets were compressed at 15 MPa, these could begin to 
float at 20 minutes whereas at a force of 32 MPa the time was prolonged to 45 minutes. 
Radiographic studies on 6 healthy male volunteers revealed that floating tablets were 
retained in stomach for 6 hours and further blood analysis studies showed that 
bioavailability of these tablets was 1.8 times that of the conventional tablets. On 
measuring the volume of urine the peak diuretic effect seen in the conventional tablets 
was decreased and prolonged in the case of floating dosage form. 
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Figure.3.  Schematic presentation of working of a triple-layer system. (A) Initial 
configuration of triple-layer tablet. (B) On contact with the dissolution medium the 
bismuth layer rapidly dissolves and matrix starts swelling. (C) Tablet swells and 
erodes. (D) And (E) Tablet erodes completely. 
B. Floating Capsules 
Floating capsules are prepared by filling with a mixture of sodium alginate and 
sodium bicarbonate. The systems were shown to float during in vitro tests as a result of 
the generation of CO2 that was trapped in the hydrating gel network on exposure to an 
acidic environment. 
C. Multiple Unit Type Floating Pills 
The system consists of sustained release pills as ‘seeds’ surrounded by double 
layers. The inner layer consists of effervescent agents while the outer layer is of swellable 
membrane layer. When the system is immersed in dissolution medium at body temp, it 
sinks at once and then forms swollen pills like balloons, which float as they have lower 
density. This lower density is due to generation and entrapment of CO2 within the system. 
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 B. Inflatable Gastrointestinal Delivery Systems 
In these systems an inflatable chamber is incorporated, which contains liquid 
ether that gasifies at body temperature to cause the chamber to inflate in the stomach. 
These systems are fabricated by loading the inflatable chamber with a drug reservoir, 
which can be a drug impregnated polymeric matrix, encapsulated in a gelatin capsule. 
After oral administration, the capsule dissolves to release the drug reservoir together with 
the inflatable chamber. The inflatable chamber automatically inflates and retains the drug 
reservoir compartment in the stomach. The drug continuously released from the reservoir 
into the gastric fluid.  
 
Figure 7.  Inflatable gastrointestinal delivery system 
C. Intragastric Osmotically Controlled Drug Delivery System  
It is comprised of an osmotic pressure controlled drug delivery device and an 
inflatable floating support in a biodegradable capsule. In the stomach, the capsule quickly 
disintegrates to release the intra-gastric osmotically controlled drug delivery device. The 
inflatable support inside forms a deformable hollow polymeric bag that contains a liquid 
that gasifies at body temperature to inflate the bag. The osmotic pressure controlled drug 
delivery device consists of two components; drug reservoir compartment and an 
osmotically active compartment. The drug reservoir compartment is enclosed by a 
pressure responsive collapsible bag, which is impermeable to vapour and liquid and has a 
drug delivery orifice. The osmotically active compartment contains an osmotically active 
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salt and is enclosed within a semipermeable housing. In the stomach, the water in the GI 
fluid is continuously absorbed through the semipermeable membrane into osmotically 
active compartment to dissolve the osmotically active salt. The osmotic pressure thus 
created acts on the collapsible bag and in turn forces the drug reservoir compartment to 
reduce its volume and activate drug release through the delivery orifice.  
The floating support is also made to contain a bioerodible plug that erodes after a 
predetermined time to deflate the support. The deflated drug delivery system is then 
emptied from the stomach. 
 
Figure 8.  Intragastric osmotically controlled drug delivery system 
 Bioadhesive Drug Delivery System 
Bioadhesion/Mucoadhesion for Oral Drug Delivery  
The term bioadhesion is defined as adhesion to biological surface i.e. mucus 
and/or mucosal surface. In instances when the polymeric system interacts with mucus 
layer only, it is referred as mucoadhesion. In order to develop an ideal oral bioadhesive 
system, it is important to have a through understanding of mucosa, bioadhesive polymers 
and mucin-polymer interactions in the physiological environment. 
Intestinal mucosa is composed of high molecular weight glycoproteins hydrated 
and covering the mucosa with a continuous adherent blanket. Mucin glycoproteins are 
Chapter-1                                                                                                                         Introduction 
 
Padmavathi College of Pharmacy and Research Institute  16 
 
rich with fucose and sialic acid groups at the terminal ends which provide a net negative 
charge in the acidic environment. The thickness of the mucin gel layer varies in different 
regions of the GIT with thickness ranging between 50-500 μm in stomach to 15-150μm 
in the colon. Cohesion of the mucin gel is dependent upon the glycoprotein 
concentration. The mucus layer is created biologically to play a number of important 
functions of protecting the underlying tissues from various diffusing/corrosive elements 
such as enzymes, acid and other toxic molecules. Also being a visco-elastic gel, it helps 
in the passage of food over the epithelium, thereby minimizing potential erosive 
damages. The mucus layer, in addition to providing protection, provides a barrier to drug 
absorption.  
Various investigators have proposed different mucin-polymer interactions, such as 
• Wetting and swelling of the polymer to permit intimate contact with the biological 
tissue      
• Interpenetration of bioadhesive polymer chains and entanglement of polymer and 
mucin chains. 
• Formation of weak chemical bonds 
• Sufficient polymer mobility to allow spreading 
• Water transport followed by mucosal dehydration (Lehr, 1992; Mortazavi, 1993). 
As the mucus layer comes into contact with bioadhesive coated system, various 
non-specific (Vander Waals, hydrogen bonding and/or hydrophobic interactions) or 
specific interactions occur between the complimentary structures. However, these 
interactions last only until the turnover process of mucin and, in order for a bioadhesive 
system to be successful; it should release its drug contents during this limited adhesion 
time. 
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Raft-Forming Systems 
Here, a gel-forming solution (e.g. sodium alginate solution containing carbonates 
or bicarbonates) swells and forms a viscous cohesive gel containing entrapped CO2 
bubbles on contact with gastric fluid. Formulations also typically contain antacids such as 
aluminium hydroxide or calcium carbonate to reduce gastric acidity. Because raft-
forming systems produce a layer on the top of gastric fluids, they are often used for 
gastro esophageal reflux treatment as with liquid gaviscon. 
 
Figure  9.  Schematic illustration of the barrier formed by a raft-forming system 
 Low Density Systems 
Gas-generating systems inevitably have a lag time before floating on the stomach 
contents, during which the dosage form may undergo premature evacuation through the 
pyloric sphincter. Low-density systems (<1 g/cm3) with immediate buoyancy have 
therefore been developed. They are made of low-density materials, entrapping oil or air. 
Most are multiple unit systems, and are also called ‘‘microballoons’’ because of the low-
density core (Sato and Kawashima, 2004).  Generally, techniques used to prepare hollow 
microspheres involve simple solvent evaporation or solvent diffusion methods. 
Polycarbonate, Eudragit S, cellulose acetate, calcium alginate, agar and low methoxylated 
pectin are commonly used as polymers. Buoyancy and drug release are dependent on 
quantity of polymer, the plasticizer–polymer ratio and the solvent used.        
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Figure 10.  (a) Microballoons (b) Foam-particles 
 Expandable Systems 
A dosage form in the stomach will withstand gastric transit if it is bigger than the 
pyloric sphincter (Caldwell et al., 1988). However, the dosage form must be small 
enough to be swallowed, and must not cause gastric obstruction either singly or by 
accumulation. Thus, three configurations are required, a small configuration for oral 
intake, an expanded gastroretentive form and a final small form enabling evacuation 
following drug release. 
                   Unfoldable systems are made of biodegradable polymer; the concept is to 
make a carrier, such as a capsule, incorporating a compressed system, which extends in 
the stomach. (Caldwell et al., 1988) proposed different geometric forms (tetrahedron, 
ring or planar membrane (4-lobed, disc or 4-limbed cross form) of biodegradable 
polymer compressed within a capsule.  
  Swellable System 
   Swellable systems are also retained because of their mechanical properties. The 
swelling usually results from osmotic absorption of water. The dosage form is small 
enough to be swallowed, and swells in gastric liquids, the bulk enable gastric retention 
and maintains the stomach in a ‘fed’ state, suppressing housekeeper waves. 
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            (Mamajek and Moyer) patented drug reservoirs, surrounded by a swellable 
expanding agent. (Urquhart and Theeqwes 1984) developed a system containing tiny 
pills, with a very high swelling ratio enabling up to 50 fold volume increase. They were 
coated by wax to control drug release and dispersed in a matrix of polymeric hydrogel.   
 
Figure 11.  Swellable systems  
  Super Porous Hydrogels 
            Although these are swellable systems, they differ sufficiently from the 
conventional types to warrant separate classification (Chen and park, 2000) with pore 
size ranging between 10 nm and 10 μm. Absorption of water by conventional hydrogel is 
very slow process and several hours may be needed to reach an equilibrium state during 
which premature evacuation of the dosage form may occur. Superporous hydrogel, 
average pore size > 100 μm, swell to equilibrium size within a minute, due to rapid water 
uptake by capillary wetting through numerous interconnected open pores. Moreover they 
swell to a large size (swelling ratio 100 or more) (Figure 11) and are intended to have 
sufficient mechanical strength to withstand pressure by gastric contractions. This is 
achieved by a co- formulation of a hydrophilic particulate material, Ac-Di-Sol (cross 
carmellose sodium). 
             In vivo studies with dogs showed that under fasting conditions, the superporous 
hydrogel composite (i.e. containing Ac-Di-Sol) remained in the stomach for 2-3 hours. 
This time increased to >24 hours after feeding, even though the fed condition was 
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maintained only for a few hours. After several hours (30 hours), fragmentation occurred 
and the composite was rapidly cleared.   
 
Figure 12.  On the left, superporous hydrogel in its dry (a) and water-swollen (b) 
state. On the right, schematic illustration of the transit of superporous hydrogel. 
 Magnetic System 
These systems appear as small gastroretentive capsules containing a magnetic 
material, whose elimination from the stomach is prevented by the interaction with a 
sufficiently strong magnet applied to the body surface in the region of the stomach. 
Despite numerous reports about successful tests, the real applicability of such systems is 
doubtful because the desired results can be achieved only provided that the magnet 
position is selected with very high precision. Probably, the development of new 
conveniently applied magnetic field sources will improve this concept. 
 Self-Unfolding Systems  
The self-unfolding systems are capable of mechanically increasing in size relative 
to the initial dimensions. This increase prevents the system from passing via the pylorus 
and provides for its prolonged stay in the stomach. A drug can be either contained in a 
polymeric composition of the gastroretentive system or included as a separate 
component. Several methods were suggested to provide for the self-unfolding effect. 
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(1) The use of hydrogels swelling in contact with the gastric juice. 
(2) Osmotic systems, comprising an osmotic medium in a semipermeable membrane. 
(3) Systems based on low-boiling liquids converting into a gas at the body temperature.                       
   This imparts to the system a desired volume and provides for the drug release. 
There are several problems for these systems, the main of which is the short 
swelling time (within several hours) insufficient for keeping the system in the stomach. 
 High Density Systems 
Gastric contents have a density close to water (1.004 g /cm3). When the patient is 
upright small high-density pellets sink to the bottom of the stomach where they become 
entrapped in the folds of the antrum and withstand the peristaltic waves of the stomach 
wall. A density close to 2.5 g/cm3 seems necessary for significant prolongation of gastric 
residence time and barium sulphate, zinc oxide, iron powder, titanium dioxide are used as 
excipients. 
1.3. GASTRORETENTIVE DRUG DELIVERY SYSTEM  
Gastroretentive dosage forms are drug delivery systems which remain in the 
stomach for an extended period of time and allow both spatial and time control of drug 
liberation. Basically gastroretentive systems swells following ingestion and is retained in 
the stomach for a number of hours, while it continuously releases the incorporated drug at 
a controlled rate to preferred absorption sites in the upper intestinal tract. Their 
application can be advantageous in the case of drugs absorbed mainly from the upper part 
of GIT or are unstable in the medium of distal intestinal regions. They can also be used 
beneficially in the local therapy of the stomach.                                            
GRDFS can be used as carriers for drugs with so called absorption windows. 
These substances for example antiviral, antifungal and antibiotic agents 
(Cephalosporin’s, Quinolones, Penicillin’s, Sulphonamides, Aminoglycosides, 
Tetracycline’s etc) are taken up only from very specific sites of GIT. In addition, by 
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continuously supplying drug to its most efficient site of absorption, the dosage forms 
allow for more effective oral use of peptide and protein drugs such as Calcitonin, 
Erythropoietin, Vasopressin, Insulin Low molecular weight, Heparin and Protease 
inhibitors.  
Prolonged gastric retention of the drugs may offer numerous advantages including 
improved bioavailability, therapeutic efficacy and possible reduction of dosage size 
(Sanjay Garg and Shring Sharma, 2003). 
However standard controlled  released dosage forms offer only limited advantages 
for drugs that have an absorption window in the upper small intestinal. (Eg: Levodopa, 
Furosemide, Riboflavin). Once emptied from the stomach, the passage through this 
region is rapid, thus limiting the extent of absorption at this site. In order to increase the 
bioavailability of this type of drugs, the residence time of the controlled-released dosage 
forms in the upper GIT needs to be prolonged (Alexander, 2006). 
1.3.1. Drugs that would benefit from GRDDS 
1) CNS drugs (for epilepsy, Alzheimer and migraine). 
2) Anti-viral products (for HIV, herpes and hepatitis) and certain antibiotics.  
3) Anti-hypertension drugs. 
4) Anti-diabetic agents for Type 2 diabetes. 
5) Drugs for local treatment of GI infections and gastric enzyme replacement (N.K. Jain). 
1.3.2. Importance of GI Absorption for Oral Drugs 
        Oral drug administration is by far the most preferable route for taking medications. 
However, the therapeutic window of many drugs is limited by their short circulating half-
life and absorption via a defined segment of the intestine. Such pharmacokinetic 
limitations lead in many cases to frequent dosing of these medications to achieve the 
required therapeutic effect. This results in "pill burden" and consequently, decreased 
patient compliance. The phenomenon of absorption via a limited part of the GI tract has 
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been termed the "narrow absorption window"; once the dosage form passes the 
absorption window, the drug will be neither bioavailability nor effective. In extreme 
cases, drugs that are insufficiently absorbed due to narrow absorption cannot be delivered 
entirely, and are either given by a parenteral route or the development of such 
medication, which is otherwise safe and effective, is stopped altogether. A rational 
approach to enhance bioavailability and improve pharmacokinetic and pharmacodynamic 
profiles is to retain the drug reservoir above its absorption area, i.e. in the stomach and to 
release the drug in a controlled manner, so as to achieve a zero order kinetics (i.e. "oral 
infusion") for a prolonged period of time (Michel, 2005). 
1.3.3. Formulation Considerations For GRDDS 
1) Drug must be effective retention in the stomach to suit for the clinical demand. 
2) It must be convenient for intake to facilitate patient compliance. 
3) Device must have sufficient drug loading capacity. 
4) It must be control the drug release profile. 
5) It must have full degradation and evacuation of the system once the drug release 
is over. 
6) It should not have effect on gastric motility including emptying pattern. 
7) It should not have other local adverse effects (Davis, 2005). 
1.3.4. Advantages of Gastroretentive Drug Delivery System 
          Gastroretentive drug delivery systems have numerous advantages listed below 
1. The principle of HBS can be used for any particular medicament or class of 
medicament. 
2. The HBS formulations are not restricted to medicaments, which are principally 
absorbed from the stomach. Since it has been found that these are equally 
efficacious with medicaments which are absorbed from the intestine e.g. 
Chlorpheniramine maleate. 
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3. The HBS are advantageous for drugs absorbed through the stomach e.g. ferrous 
salts and for drugs meant for local action in the stomach and treatment of peptic 
ulcer disease e.g. Antacids. 
4. The efficacy of the medicaments administered utilizing the sustained release 
principle of HBS has been found to be independent of the site of absorption of the 
particular medicaments. 
5. Administration of a prolonged release floating dosage form tablet or capsule will 
result in dissolution of the drug in gastric fluid. After emptying of the stomach 
contents, the dissolved drug available for absorption in the small intestine. It is 
therefore expected that a drug will be fully absorbed from the floating dosage 
form if it remains in solution form even at alkaline pH of the intestine. 
6. When there is vigorous intestinal movement and a short transit time as might 
occur in certain type of diarrhoea, poor absorption is expected under such 
circumstances it may be advantageous to keep the drug in floating condition in 
stomach to get a relatively better response. 
7. Gastric retention will provide advantages such as the delivery of drugs with 
narrow absorption windows in the small intestinal region.  
8. Many drugs categorized as once-a-day delivery have been demonstrated to have 
sub optimal absorption due to dependence on the transit time of the dosage form, 
making traditional extended release development challenging. Therefore, a system 
designed for longer gastric retention will extend the time within which drug 
absorption can occur in the small intestine. (Gutierrez et al., 2003). 
1.3.5. Disadvantages of Gastroretentive Drug Delivery System 
1. There are certain situations where gastric retention is not desirable. Aspirin and 
non-steroidal anti-inflammatory drugs are known to cause gastric lesions and slow 
release of such drugs in the stomach is unwanted. 
2. Thus, drugs that may irritate the stomach lining or are unstable in its acidic 
environment should not be formulated in gastroretentive systems. 
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3. Furthermore, other drugs, such as Isosorbide Dinitrate, that are absorbed equally 
well throughout the GI tract will not benefit from incorporation into a gastric 
retention system (Hou et al., 2003). 
4. Gastric retention is influenced by many factors such as gastric motility, pH and 
presence of food. These factors are never constant and hence the buoyancy cannot 
be predicted exactly or accurately. 
5. Gastric emptying of floating forms in supine subjects may occur at random and 
become highly dependent on the diameter. Therefore, patients should not be 
dosed with floating forms just before going to bed.  
6. High variability in gastric emptying time due to variations in emptying process. 
7. Unpredictable bioavailability. 
         1.3.6. Limitations 
1. The major disadvantage of floating system is requirement of a sufficient high 
level of fluids in the stomach for the drug delivery to float. However this 
limitation can be overcome by coating the dosage form with the help of 
bioadhesive polymers that easily adhere to the mucosal lining of the stomach 
2. Floating system is not feasible for those drugs that have solubility or stability 
problem in gastric fluids. 
3. The dosage form should be administered with a minimum of glass full of water 
(200-250 mL). 
4. The drugs, which are absorbed throughout gastro-intestinal tract, which under go 
first-pass metabolism (Nifedipine, Propranolol etc.) are not desirable candidate. 
5. Some drugs present in the floating system causes irritation to gastric mucosa 
(Chien, 1992). 
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  1.3.7. Factors Affecting the Gastroretentive System 
Various attempts have been made to retain the dosage form in the stomach as a 
way of increasing the retention time. These attempts include use of floating dosage forms 
(gas-generating systems and swelling or expanding systems), mucoadhesive systems, 
high-density systems, modified shape systems, gastric-emptying delaying devices and co-
administration of gastric-emptying delaying drugs. Most of these approaches are 
influenced by a number of factors that affect their bioavailability and efficacy of the 
gastro retentive system (Sanjay et al., 2003). 
• Density – Gastric retention time (GRT) is a function of dosage form buoyancy 
that is dependent on the density. 
• Size – Dosage form units with a diameter of more than 7.5 mm are reported to 
have an increased GRT compared with those with a diameter of 9.9 mm. 
• Shape of dosage form – Tetrahedron and ring shaped devices with a flexural 
modulus of 48 and 22.5 kilo pounds per square inch (KSI) are reported to have 
better GRT 90% to 100% retention at 24 hours compared with other shapes. 
• Single or multiple unit formulation – Multiple unit formulations show a more 
predictable release profile and insignificant impairing of performance due to 
failure of units, allow co-administration of units with different release profiles or 
containing incompatible substances and permit a larger margin of safety against 
dosage form failure compared with single unit dosage forms. 
• Fed or unfed state – Under fasting conditions, the GI motility is characterized by 
periods of strong motor activity or the migrating myoelectric complex (MMC) 
that occurs every 1.5 to 2 hours. The MMC sweeps undigested material from the 
stomach and, if the timing of administration of the formulation coincides with that 
of the MMC, the GRT of the unit can be expected to be very short. However, in 
the fed state, MMC is delayed and GRT is considerably longer. (Caldwell et al., 
1998; Murthy et al., 2000). 
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• Nature of meal – Feeding of indigestible polymers or fatty acid salts can change 
the motility pattern of the stomach to a fed state, thus decreasing the gastric 
emptying rate and prolonging drug release.  
• Caloric content – GRT can be increased by 4 to10 hours with a meal that is high 
in proteins and fats (Marvola et al., 1989) (Mojaverian et al., 1988). 
• Frequency of feed – The GRT can increase by over 400 minutes when successive 
meals are given compared with a single meal due to the low frequency of MMC. 
• Gender – Mean ambulatory GRT in males (3.4±0.6 hours) is less compared with 
their age and race matched female counterparts (4.6±1.2 hours), regardless of the 
weight, height and body surface. 
• Age – Elderly people, especially those over 70, have a significantly longer GRT. 
• Posture – GRT can vary between supine and upright ambulatory states of the 
patient. 
• Concomitant drug administration – Anticholinergics like atropine and 
propantheline, opiates like codeine and prokinetic agents like metoclopramide and 
cisapride can affect floating time. 
• Biological factors – Diabetes and Crohn’s disease, etc. 
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1.4.   ESOMEPRAZOLE MAGNESIUM TRIHYDRATE 
Esomeprazole is the S-enantiomer of omeprazole, has higher oral bioavailability. 
Esomeprazole belongs to the category of proton pump Inhibitors used in the treatment of 
peptic ulcers. Esomeprazole inhibits the final step in the gastric acid secretion.  
Esomeprazole is a specific inhibitor of a proton pump (PPIs) of the parietal cells 
of the mucous layer of stomach. It is a form of omeprazole. It is accumulated and 
transformed into an active form in the secretory tubules where it inhibits secretion of 
hydrochloric acid, Esomeprazole is used to treat Gastro Esophageal Reflux Disease 
(GERD), Zollinger-Ellison syndrome, promote healing of erosive esophagitis, eradication 
of helicobacter pylori together with antibiotics, in the preventive therapy of ulcers. 
Esomeprazole produces complete inhibition of gastric acid resulting in rapid 
symptom relief and more effective in promoting healing of esophageal lesions. It is the 
drug of choice for patients with frequent or chronic symptoms in gastric erosions.  
The initial dose is 20 mg once daily. In chronic cases, the dose may range from 
20-60 mg in one or two doses daily.  
It has more bioavailability than omeprazole. The t1/2   is about 1.3 hours and has a 
of bioavailability 60%. Significant pharmacological action is the suppression of gastric 
acid secretion without H2 receptor blocking action. It is a powerful inhibitor of gastric 
acid and totally abolishes HCl secretion. It is a drug of choice for patients with 
frequent/chronic symptoms in Gastro Esophageal Reflux Disease (GERD). 
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¾ Shah S.H. et. al., (2005) Technological attempts have been made in the research 
and development of rate-controlled oral drug delivery systems to overcome 
physiological adversities, such as short gastric residence times (GRT) and 
unpredictable gastric emptying times (GET). It is known that differences in gastric 
physiology, such as, gastric pH, and motility exhibit both intra-as well as inter-
subject variability demonstrating significant impact on gastric retention time and 
drug delivery behavior. This triggered the attention towards formulation of stomach 
specific (gastro retentive) dosage forms. This dosage forms will be very much 
useful to deliver ‘narrow absorption window’ drug delivery system (FDDS), 
swelling and expanding systems, polymeric bioadhesive system, high-density 
systems, modified-shape systems and other delayed gastric emptying devices. 
 
¾ Lodhe S. et. al.,  (2008) Verapamil hydrochloride bi-layer floating tablets have two 
layers one immediate release layer and second floating sustained release layer. 
Verapamil hydrochloride bi-layer floating tablet releases drug in two phases i.e 
immediate and sustained drug release. Direct compression method was used to 
formulate bi-layer floating tablets. All bi-layer formulation float more than 12 h and 
sustained drug release above 12 h. Kinetic release study suggests that release 
mechanism is quasi Fickian. The optimized formulation was selected based on in 
vitro characteristics and used in vivo radiographic studies in rabbits by 
incorporating BaSO4. This showed that, tablet significantly float in rabbit stomach 
for more than 7 h. 
 
 
¾ Singh Badana et. al.,(2000) Designed an experiment for present preparation of 
famotidine floating microspheres, evaluation of Floating Drug Delivery System 
(FDDS) in vitro, prediction of the release, and optimization of stirring speed and 
polymers ratio to match target release profile was investigated. Floating 
microspheres were prepared by solvent evaporation (Oil-in-water emulsion) 
technique using hydroxylpropyl methylcellulose (HPMC) and Ethylcellulose (EC) 
as the rate controlling polymers. Particle size analysis, drug entrapment efficiency, 
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surface topography, buoyancy percentage and release studies were performed. 
Results showed that the polymer ratio and stirring speed affected the size, 
incorporation efficiency and drug release of microspheres (> 12 h), floating time (> 
12 hr) and the best result were obtained at the ratio of HPMC:EC (1:6). The mean 
particle size of prepared floating microspheres increased but the drug release rate 
from the microspheres decreased as the polymer concentration increased. The 
developed floating microspheres of famotidine may be used in clinic for prolonged 
drug release in stomach for at least 12 hrs, thereby improving the bioavailability 
and patient compliance.  
 
¾ Khan et. al., (2009) Investigated preparation and in vitro evaluation of 
gastroretentive floating tablet of theophylline. Two hydrophilic cellulose 
derivatives, Methocel K100M and Methocel K15MCR, were evaluated for their gel 
forming and release controlling properties. Sodium bicarbonate and citric acid were 
incorporated as gas generating agents. The effects of soluble components (sodium 
bicarbonate and citric acid), gel forming agents and amount variation of 
theophylline on drug release profile and floating properties were investigated. 
 
 
¾ Gattani et. al., (2008) Formulated and evaluated floating multiparticulate oral DDS 
of diltiazem hydrochloride, which can provide SR. The work also aims to study 
various parameters affecting the behavior of floating multiparticulate in oral dosage 
form. FM were prepared by non-aqueous emulsification solvent evaporation 
technique using ethyl cellulose (EC) and Eudragit RS-100 as the rate controlling 
polymer. The in vitro performance was evaluated by the usual pharmacopoeial and 
other tests such as drug-polymer compatibility, (%) yield, particle size analysis, 
drug entrapment efficiency, surface topography, in vitro floatability and release 
studies. The data obtained in this study thus suggest that a microparticulate floating 
dosage form of Diltiazem hydrochloride can be successfully designed to give 
controlled delivery and improved oral bioavailability. 
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¾ Rao et. al., (2009) Prepared and evaluated FM of rosiglitazone maleate for the 
prolongation of GRT. The microspheres were prepared by solvent diffusion-
evaporation method using EC and HPMC. A full factorial design was applied to 
optimize the formulation. The results of 3 2 full factorial design revealed that the 
concentration of ethylcellulose 7 cps (X1) and stirring speed (X2) significantly 
affected drug entrapment efficiency, percentage release after 8 hours and particle 
size of microspheres. 
 
 
¾ Deepaa et. al., (2009) Developed FM of cefpodoxime proxetil in order to achieve 
an extended retention in the upper GIT, which may result in enhanced absorption 
and thereby improved bioavailability. The microspheres were prepared by non-
aqueous solvent evaporation method using polymers such as HPMC K15M, EC in 
different ratios and Cefpodoxime Proxetil in each formulation. The best drug 
release profiles were seen with formulation 2 at the ratio of drug to polymer of 1:2. 
 
¾ Ali et. al., (2007)  Developed an HBS of Metformin as a single-unit floating 
capsule. Various grades of low-density polymers were used for the formulation of 
this system. Capsules prepared with HPMC K4M and EC gave the best in vitro 
percentage release and were taken as the optimized formulation. In vivo studies 
were carried out in rabbits to assess the buoyancy as well as the pharmacokinetic 
parameters of the formulation using gamma scintigraphy. The formulation remained 
buoyant during 5 hours of study in rabbits. The comparative pharmacokinetic study 
was performed by administration of the optimized HBS capsules and immediate 
release capsules, both with radiolabeled metformin, using gamma counter. There 
was an increase in AUC in optimized HBS capsules of metformin when compared 
with immediate release formulation. 
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¾ Jain et. al., (2005) Developed a CR system to increase its residence time in the 
stomach without contact with the mucosa. This aim was achieved through the 
preparation of FM by the emulsion solvent diffusion technique consisting of 
Calcium Silicate Florite (RE, FLR) as a porous carrier, Repaglinide, an oral 
hypoglycemic agent, and Eudragit as a polymer. Incorporation of FLR in the 
microspheres proved to be an effective method to achieve the desired release 
behavior and buoyancy. The designed systems, combining excellent buoyant ability 
and suitable drug release pattern, could possibly be advantageous in terms of 
increased bioavailability of Repaglinide. 
 
¾ El-Kamel et.al., (2001) Designed an SR system for Ketoprofen to increase its 
residence time in the stomach without contact with mucosa through the preparation 
of FM by the emulsion solvent diffusion technique. The floating multi-unit system 
for Ketoprofen was prepared using Eudragit RS 100 (ES) alone or in a mixture with 
the permeable Eudragit RL (ERL). The floating microparticles of Ketoprofen 
prepared with a suitable ratio of ES 100 to ERL provided a convenient dosage form 
for achieving best performance regarding flow, release and floating properties. 
 
 
¾ Sato et.  al., (2004) investigated the intragastric behavior of 99mTc labeled MB and 
non-floating microspheres (NF) of riboflavin following oral administration in fasted 
and fed humans by gamma scintigraphy. Simultaneously, pharmacokinetic 
examination of riboflavin released from MB and NF was conducted in fasted and 
fed human subjects. The investigation suggests that MB are very useful for 
improving drug bioavailability, resulting in a more sustained pharmacological 
action. 
 
¾ Dave et. al.., (2004) developed a Gastroretentive DDS of ranitidine hydrochloride 
using guar gum, xanthan gum, and HPMC. Sodium bicarbonate was incorporated as 
a gas-generating agent. The effect of citric acid and stearic acid on drug release 
profile and floating properties was investigated. A 3 2 full factorial design was 
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applied to systemically optimize the drug release profile and the results showed that 
a low amount of citric acid and a high amount of stearic acid favored SR of 
ranitidine hydrochloride from a gastroretentive formulation. 
 
 
¾ Sato et. al., (2004) prepared MB of riboflavin by the emulsion solvent diffusion 
method. The objective of the investigation was to assess the usefulness of 
intragastric buoyant properties in terms of sustained pharmacological action in 
humans. NF were prepared in order to effect comparison with MB; moreover, in 
vivo evaluation of MB and NF in humans was conducted. Pharmacokinetics was 
examined via analysis of urinary excretion of riboflavin adopted as a model drug 
following oral administration of MB. 
 
¾ Streubel et.al., (2003) developed a single-unit FDDS of Diltiazem, Theophylline 
and Verapamil, which was based on low-density foam power and matrix-forming 
polymer(s). The drug release patterns can effectively be adjusted by varying simple 
formulation parameters such as the "matrix-forming polymer/foam power" ratio, 
initial drug loading, tablet height and diameter, type of matrix-forming polymer, 
addition of water-soluble and water-insoluble fillers and the use of polymer blends. 
Thus, desired release profiles adapted to the pharmacokinetic/pharmacodynamic 
properties of the incorporated drug can easily be provided. 
 
 
¾ EL-Gibaly et. al., (2002) prepared floating microcapsules containing melatonin by 
the ionic interaction of Cs and a negatively charged surfactant, sodium Dioctyl 
sulfosuccinate (DOS). The effect of various factors (cross-linking time, DOS and 
Cs concentration, as well as drug/polymer ratio) on microcapsule properties was 
evaluated. Cs concentration and drug/polymer ratio had a remarkable effect on drug 
entrapment in DOS/Cs microcapsules. 
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¾ Patil et. al., (2009) prepared FM of Metformin hydrochloride by non-aqueous 
emulsification solvent evaporation technique using EC as the rate-controlling 
polymer. The experimental design supported product development and optimization 
procedure yielded the desired microspheres with drug release equivalent to those of 
the marketed single-unit dosage forms with the added advantage of floatability in 
gastric juice for prolonged slow release. 
 
 
¾ Choi et. al.,(2002) prepared alginate beads of riboflavin for FDDS. The effects of 
gas-forming agents CaCO 3 /NaHCO 3 on beads' size, floating ability, pore 
structure, morphology, release rate and mechanical strength of floating beads were 
investigated. In general, CaCO 3 formed smaller and stronger floating beads than 
NaHCO3 . Although CaCO 3 is a less effective gas-forming agent than NaHCO 3 , it 
produced superior floating beads with enhanced control of drug release rates. 
 
¾ Srivastava et. al.,(2005) prepared FM of Cimetidine by the solvent evaporation 
method using the polymers HPMC and EC. In vitro data obtained for FM showed 
excellent floatability, good buoyancy and prolonged drug release. Microspheres of 
different sizes and drug content could be obtained by varying the formulation 
variables. 
 
 
¾ Krogel et.al., (1999) developed and evaluated floating and pulsatile DDS of 
Chlorpheniramine Maleate based on a reservoir system consisting of a drug-
containing effervescent core and a polymeric coating. Ideally, the expansion of the 
core could result in 
1. A floating dosage form with a prolonged residence time and extended drug 
release or 
2. A pulsatile dosage form, in which the drug is released rapidly in a time-
controlled fashion after rupturing of the coating. 
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AIM AND OBJECTIVE 
 To design, formulate & carryout the in-vitro evaluation studies on Gastroretentive 
floating microspheres of Esomoprazole Magnesium Trihydrate. 
 The main objective of the study was to formulate and evaluate Gastroretentive Floating 
microspheres of Esomeprazole Magnesium Trihydrate which is expected to deliver the drug in 
controlled manner with reduced frequency of drug administration, improve patient compliance & 
bioavailability of Esomeprazole Magnesium Trihydrate. 
 Presently in India Esomeprazole is available as 20-40 mg tablets in which dose quantity 
is optimum, bioavailability is less due to rapid systemic metabolism in the acidic pH. 
 The half-life of Esomeprazole is less than 3 hours. So a controlled-release formulation of 
Esomeprazole would increase the length of time release in which Esomeprazole achieves an 
effective concentration in the GIT. 
 This study mainly deals in the design of a formulation which produces time controlled 
prolonged drug release and to enhance the bioavailability of the drug to about 90% and also to 
reduce the dosing interval of the drug. 
  
 
 
 
Chapter-4                                                                                                                      Plan Of Work 
 
Padmavathi College of Pharmacy and Research Institute   36 
 
PLAN OF WORK 
Present work was carried out to design and evaluate the Floating microspheres of 
Esomeprazole Magnesium Trihydrate. 
1) Selection of drug 
2) Literature survey 
3) Preformulation studies 
a) Identification of drug 
• Physical appearance 
• Melting point 
• FT-IR spectra 
b) Solubility studies 
c) Drug-excipients interaction 
d) FTIR study for drug excipient interaction 
e) Quantitative estimation of drug 
f) Determination of absorption maxima (λmax) 
4) Preparation of standard curve in Phosphate buffer pH 7.0 
5) Preparation of Floating microspheres 
6) Characterization of prepared Floating microspheres 
a) Determination of drug content 
b) Entrapment efficiency 
c) Determination of particle size 
d) Surface morphology by SEM 
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7) Evaluation of the prepared floating microspheres of Esomeprazole 
magnesium trihydrate 
a) Angle of repose 
b) Bulk density 
c) In vitro dissolution studies n phosphate buffer 7.4 pH buffer 
d) Interpretation of drug release mechanism by kinetic models 
• Zero-order 
• First order 
• Higuchi model 
• Korsmeyer-Peppas model 
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MATERIALS AND METHODS 
The following materials were used as supplied by the manufacturers. 
5.1. Materials Used 
 
5.2. Equipments Used  
 
 
 
 
S. No. Chemicals Supplied by 
1 Esomeprazole Magnesium Trihydrate Microlabs, Bangalore 
2 HPMC Oxford Laboratories, Mumbai 
3 Chitosan Central Institute of Fisheries, Kerala 
4 Sodium Alginate S.D. Fine Chem. Ltd, Mumbai 
5 Sodium Bicarbonate S.D. Fine Chem. Ltd, Mumbai 
6 DichloroMethane S.D. Fine Chem. Ltd, Mumbai 
7 Ethanol S.D. Fine Chem. Ltd, Mumbai 
8 Petroleum Ether S.D. Fine Chem. Ltd, Mumbai 
9 η-hexane S.D. Fine Chem. Ltd, Mumbai 
S. No. Equipment Supplied by 
1 Dissolution test apparatus USP ROTATING Basket Dissolution 
2 Remi Stirrer No. 1A323 Instrument and Appliances Mfg. Corporation, 
3 UV-Visible Spectrometer Model SCHIMADZU  UV-Vis spectrometer 
4 Dryer: Hot Air Oven PSM Industries, Bangalore 
5 Electro Balance K. Roy & Company, Varanasi 
6 Scanning Electron microscope JSM 35CF, JEOL, Japan 
7 Sieve Shaker Toshniwal, India 
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5.3 DRUG PROFILE 
ESOMEPRAZOLE MAGNESIUM TRIHYDRATE 
  Esomeprazole is the S-enantiomer of omeprazole. Esomeprazole belongs to the category 
of proton pump Inhibitors used in the treatment of peptic ulcers.   
Chemical Name    :    bis(5-methoxy-2-[(s)-[(4-methoxy-3,5-dimethyl-2-pyridinyl) 
                                              Methyl]sulinyl]-1H-benzimidazole-l-yl)magnesium                                             
                                              Trihydrate.    
Molecular Formula    :        (C17H18N3O3S)2 Mg x 3 H2O 
Molecular weight        :         767.2 
Chemical Structure     :     
                                                                                        
Category  : Anti Ulcer 
Appearance  : It occurs as a white amorphous powder. 
Solubility                    : The drug was found to be freely soluble in the solvent 
system   i.e., Dichloromethane + ethanol in 1:1 ratio. 
Melting Point  : The melting point was found to be 155O C. 
Storage  : It is light sensitive and to be stored  in a dark place. 
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Pharmacokinetics 
 Absorption 
  Following oral administration it is less absorbed and undergoes extensive 
first pass metabolism; systemic bioavailability is about 60%. The mean peak 
concentration is reached in 1.5 hrs. 
Dose                            : 40 mg  
Onset of action             : 3 hrs 
Volume of distribution   : The  volume of distribution  is approximately 16 L. 
Excretion                            : Approximately 80% of an oral dose of esomeprazole is     
                                                     excreted as inactive metabolites in the urine, and the       
                                                    remainder is found as inactive metabolites in the feces 
PlasmaProtein binding       : 97% bound to plasma proteins 
Bioavailability                    : The systemic bioavailability is approximately  64% 
Elimination half life          : The plasma elimination half-life of esomeprazole  
     approximately 1 to 1.5 hours. 
Mechanism of Action 
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by 
specific inhibition of the H+/K+-ATPase in the gastric parietal cell. The S- and R-isomers 
of omeprazole are protonated and converted in the acidic compartment of the parietal cell 
forming the active inhibitor, the achiral sulphenamide. By acting specifically on the 
proton pump, esomeprazole blocks the final step in acid production, thus reducing gastric 
acidity.  
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5.4 EXCIPIENT PROFILE 
HYROXY PROPYL METHYL CELLULOSE 
Hydroxy propyl methylcellulose is mixed alkyl hydroxyl alkyl cellulosic ether 
and may be regarded as the propylene glycol ether of methylcellulose. 
Chemical Name   :  Cellulose, 2-hydroxypropyl methyl ether 
Synonyms      : Methyl Hydroxy Propyl cellulose, Propylene Glycol ether of 
methylcellulose, Culminal HPMC. 
Structural Formula: 
O R
C H 2 O R
O
OO
O
O
O R
O R
O R
C H 2 O R
W h e r e  R  i s  H ,  C H 3  o r  C H 3 - C H ( O H ) - C H 2  
Physical and chemical properties  
 Molecular weight : 10,000 - 15,00,000 Daltons 
 Color : White to creamy-white  
 Nature : Fibrous or granular  powder 
 Odour  : Odourless 
 Taste  : Tasteless 
 Density  : 0.3-1.3 g/ml 
 Specific gravity  : 1.26 
 Solubility  : Soluble in cold water, practically insoluble in 
Chloroform, ethanol (95%) and ether but Soluble in mixture of ethanol and 
Dichloromethane. 
 Viscosity                                        : 3,000-5600 M Pas 
   Melting point                              :  190-200 °C,                                                                                    
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Functional Category  
 Coating agent, film-forming, rate-controlling polymer for sustained release, 
stabilizing agent, suspending agent, tablet binder, viscosity-increasing agent. 
Application 
 In oral product HPMC is primarily used as tablet binder, in film coating and as an 
extended release tablet matrix. Concentration between 2-5% w/w may be used as 
a binder in either wet or dry granulation process. High viscosity grade may be 
used to retard the release of water-soluble drug from a matrix. 
 HPMC is widely used in oral and topical pharmaceutical formulation. 
 Concentration of 0.45-1% w/w may be added as a thickening agent to vehicle for 
eye drop and artificial tear solution. 
 HPMC is used as an adhesive in plastic bandage and as a wetting agent for hard 
contact lenses. It is widely used in cosmetics and food products. 
 In addition, HPMC is used as an emulsifier, suspending agent and stabilizing 
agent in topical gels and ointments. As a protective colloid, it can prevent droplets 
and particle from coalescing or agglomerating thus, inhibiting the formation of 
sediments. 
Stability and storage 
 It is stable although it is slightly hygroscopic. The bulk material should be 
stored in an airtight container in a cool and dry place. Increased in temperature reduces 
the viscosity of the solution. 
Safety  
 It is generally regarded as a non-toxic and non-irritant material so it is widely 
used in many oral and topical pharmaceutical formulations. Excessive consumption of 
HPMC may have laxative effect .  
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SODIUM BICARBONATE 
Chemical Name                              :  Carbonic acid monosodium salt 
Structural Formula : NaHCO3 
Physical and chemical properties 
Molecular weight  : 84.01 
Color                      : White   
Nature   : Crystalline powder 
Odour    : Odourless 
Taste    :  Saline/slight alkaline 
Density    :  0.869-2.173 g/cm3 
Moisture content  : less than 1%w/w 
Solubility    : Soluble in water, practically insoluble in   
                                  ethanol   (95%) and ether. 
Melting point   :  270 °C (with decomposition) 
Functional category 
 Alkalizing agent, Therapeutic agent 
Applications 
 Used in pharmaceutical formulation as a source of carbon dioxide in effervescent 
tablets and granules. 
 Used to produce or maintain an alkaline pH in a preparation, like solution of 
Erythromycin, Lidocaine, and Niacin etc. 
 Used to produce a sodium salt of the active ingredient that has enhanced 
solubility. 
 Used as a freeze-drying stabilizer and in toothpaste. 
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 Used as a gas forming agent in alginate raft system and in floating drug delivery 
system. 
Stability and Storage 
  Sodium bicarbonate is stable in dry air but slowly decomposed in moist air 
and should therefore be store in well-closed container in a cool dry place. 
Safety 
  Orally ingested sodium bicarbonate neutralizes gastric acid with the evolution 
of carbon dioxide and may cause stomach cramps and flatulence (Rowe et al., 2003) 
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SODIUM ALGINATE 
Nonproprietary Names: BP: Sodium alginate; PhEur: Natrii alginas; USPNF: 
Sodium alginate. 
Synonyms : Algin, alginic acid, sodium salt, E401, Kelcosol, Keltone, Protanal, 
sodium polymannuronate. 
Empirical Formula  
 Sodium alginate consists chiefly of the sodium salt of alginic acid, which is a 
mixture of polyuronic acids composed of residues of d-mannuronic acid and l-
gulcuronic acid.  
Functional Category  
Stabilizing agent; Suspending agent; Tablet and Capsule disintegrant; Tablet 
binder; Viscosity-increasing agent. 
Applications in Pharmaceutical Formulation or Technology 
Sodium alginate is used in a variety of oral and topical pharmaceutical 
formulations. In tablet formulations, sodium alginate may be used as both a binder 
and disintegrant. It has been used as a diluent in capsule formulations. Sodium 
alginate has also been used in the preparation of sustained-release oral 
formulations since it can delay the dissolution of a drug from tablets, capsules and 
aqueous suspensions.  
       Solubility   
Practically insoluble in ethanol (95%), ether, chloroform, and ethanol/water      
mixtures in which the ethanol content is greater than 30%.. 
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Applications 
 Used as a key component in the manufacture of mucoadhesive dosage forms and 
in controlled release formulations. Chitosan has been included in various pharmaceutical 
dosage forms such as gels, beads, microspheres, liposomes etc., 
Saftey 
 Chitosan is found to be biocompatible to both healthy and infected skin. 
 Chitosan is biodegradable polymer and can be used safely. 
Storage 
 Chitosan powder is stable at room temperature, although it is hygroscopic after 
drying. Chitosan should be stored in tightly closed container in a cool, dry place and 
should be stored at a temperature of 2-80 C. 
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PRE FORMULATION STUDY 
Prior to the development of the dosage forms the preformulation study was 
carried out. Hence Infrared spectra of the physical mixture of the drug and the polymers 
chosen were taken. The infra-red spectra of the drug and polymers were also taken. 
 The application of infra-red spectroscopy lies more in the qualitative 
identification of substances either in pure form or in the mixture and as a tool in 
establishment of the structure. Since I.R. is related to covalent bonds, the spectra can 
provide detailed information about the structure of molecular compounds. In order to 
establish this point, comparisons can be made between the spectrum of the substance and 
the drug. 
STANDARD PLOT FOR ESOMEPRAZOLE MAGNESIUM 
TRIHYDRATE 
 Standard Graph by using Phosphate Buffer (pH 7.4) 
Accurately weighed 10 mg of Esomeprazole Magnesium was dissolved in 100 ml 
of 7.4 pH buffer solution to form 100 µg/ml stock solutions. 
From this stock solution aliquots of 2.5 ml, 5 ml, 7.5 ml, 10 ml, 12.5 ml, 15 ml, 
17.5ml, 20 ml, 22.5 ml, 25 ml were pipette out into a series of 50 ml in order to get a 
concentration ranging from 5-50µg/ml. 
 The absorbance of the resulting solution was then measured at 301 nm using UV 
spectrophotometer against respective parent solvent as a blank. The standard curve was 
obtained by plotting absorbance Vs. concentration µg/ml. 
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Table No. 4 
Standard Calibration Curve of Esomeprazole Magnesium Trihydrate 
 
SL. No CONCENTRATION(µg/ml) ABSORBANCE 
1 10 0.057 
2 15 0.086 
3 20 0.115 
4 25 0.144 
5 30 0.173 
6 35 0.202 
7 40 0.231 
8 45 0.261 
9 50 0.292 
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Graph No.1 
Standard Calibaration Curve of Esomeprazole Magnesium Trihydrate 
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b) SOLUBILITY STUDIES 
 The solubility of Esomeprazole Magnesium was determined in solvents of 
different polarities. The solubility of Esomeprazole Magnesium is usually determined by 
the equilibrium solubility method, which employs a saturated solution of Esomepazole 
Magnesium, obtained by adding an excess amount of Esomeprazole Magnesium in the 
solvent to promote drug precipitation, and then stirring for 2 hr until equilibrium was 
reached. The mixture was filtered and amount of Esomeprazole Magnesium was 
determined by using UV Spectrophotomer at 301 nm. 
Table No.5 
Solubility studies of Esomeprazole Magnesium Trihydrate 
S. No. Solvents Observed 
1 PBS-7.4(pH) Freely soluble 
2 Ethanol Freely soluble 
3 Dichloro Methane Freely soluble 
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c) FT-IR SPECTRA OF ESOMEPRAZOLE MAGNESIUM 
TRIHYDRATE 
 The FT-IR analysis of the Esomeprazole magnesium was carried out for 
qualitative compound identification. The FT-IR spectra for pure drug and with other 
excipients was obtained by placing the drug directly into the cavity and was determined 
by FT-IR spectrophotometer in the wave number region of 4000-400 cm-1. 
Table No.6 
Comparison of I.R. Spectra of Esomeprazole Magnesium Trihydrate 
and in Combination with Polymers 
S. No Sample C=O (cm-1) 
-CC 
(cm-1) 
-CH 
(cm-1) 
1 
Esomeprazole 
Magnesium 
Trihydrate 
3182 1462 919 
2 EMT + HPMC 3183 1458 915 
3 EMT + Chitosan 3182 1462 919 
4 EMT + Na2CO3 3182 1495 919 
5 EMT + HPMC + Chitosan 3182 1462 919 
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Graph No. 3 
Esomeprazole Magnesium Trihydrate + HPMC 
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Graph No. 4 
Esomeprazole Magnesium Trihydrate + Chitosan 
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Graph No. 5 
Esomeprazole Magnesium Trihydrate + Sodium Bicarbonate  
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Graph No. 6 
Esomeprazole Magnesium + HPMC + Chitosan    
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Preparation of Microspheres 
 In the present study, microspheres are prepared using Emulsion-Polymerization 
method. In this method, polymeric drug solution i.e., drug + polymer and solvent system 
(DicloroMethane + Ethanol) of 10 ml is added to 10 % solution of egg albumin. This 
polymeric phase is stirred continuously to form a uniform dispersion. In another beaker 
86 ml of coconut oil containing 1 ml of 0.5% Sodium Lauryl Sulphate is taken which 
forms the organic phase. The polymeric phase is added drop wise using needle into the 
organic phase. It is continuously stirred for 2 hrs with a speed of 700 rpm using stirrer. 
After stirring 1 ml of formaldehyde is added and obtained microspheres are washed thrice 
with 20 ml of η–hexane and the obtained final microspheres are stored in a dessicator. 
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Table No. 7 
Formulation Design For Floating Microspheres of Esomeprazole 
Magnesium Trihydrate 
   
Formulation 
No. 
Drug 
(Esomeprazole 
Mg.3H2O) in 
mg 
HPMC 
(mg) 
Chitosan 
(mg) 
Sodium 
Bicarbonate 
(% W/V) 
Sodium 
Alginate  
(% W/V) 
F1 
(1:1) 
50 50 - 1 % 2 % 
F2 
(1:1.5) 
50 75 - 1 % 2 % 
F3 
(1;1) 
50 - 50 1 % 2 % 
F4 
(1;1.5) 
50 - 75 1 % 2 % 
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7.1.PARTICLE SIZE DETERMINATION 
The particle size of a pharmaceutical preparation is strictly maintained in order to get 
optimal biological activity. 
Methods to estimate particle size are 
a. Optical Microscopy 
b. Sieving Method 
c. Sedimentation Method 
d. Elutriation Method 
e. Centrifugal refractometry 
f. Permeability Method 
g. Light scattering Method 
Table No. 8 
Common techniques for measuring fine particles of various sizes 
 
 
 
 
 
S. No. Technique Particle sizes in (µm) 
1 Optical Microscopy 1-100 µm 
2 Sieving > 50 µm 
3 Sedimentation > 1 µm 
4 Elutriation 1-50 µm 
5 Centrifugation < 50 µm 
6 Permeability > 1 µm 
7 Light Scattering 0.5-50 µm 
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 7.2 . SCANNING ELECTRON MICROSCOPY 
Procedure 
 Morphology details of the specimens were determined by using a Scanning 
Electron Microscope (SEM), Model JSM 35CF, JEOL, Japan. 
 The samples were dried thoroughly in Vaccum dessicator before mounting on 
brass specimen studies. The samples were mounted on specimen studies using Double 
sided adhesive tape. The sputtering was done for nearly 3 minutes to obtain uniform 
coating on the sample to enable good quality SEM images. The SEM was operated at low 
accelerating voltage. 
 The condenser lens position was maintained between  4.4-5.1. The objective lens 
aperture has a diameter of 240 microns and the Working Distance   WD is 39 mm. 
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Fig No. 14 
Microscopic Pictures of Esomeprazole Magnesium Trihydrate Floating 
Microspheres 
 
      
 
 7.3. Flow Properties 
 Flow property depends on particle size, shape, porosity and density of 
microspheres. 
Angle of Repose 
 The flow characteristics are measured by angle of repose. Improper flow is due to 
frictional forces between the particles. These forces are quantified by angle surface of the 
pile of the powder and the horizontal plane. The flow of powder and the angle of repose 
is depicted in following table. 
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Definition 
 The lower the angle of repose, the better the flow property. Rough and irregular 
surface of particles gives higher angle of repose. Decreased in the particle size leads to a 
higher angle of repose. 
tan θ = h / r 
θ = tan -1 (h / r) 
Where, h= height of pile  
                                                              r = radius of the base of the pile    
                                                              θ = angle of repose      
Method 
 A glass funnel is held in place with a clamp on a ring support over a glass plate. 
The glass plate is placed on a stand. Approximately 100 g of particles is transferred into 
funnel keeping the office of the funnel blocked by the lower thumb. As the thumb is 
removed, the particles are emptied from funnel, and the angle of repose s determined by 
above mentioned formula. 
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Table No.9 
Relation between Angle of Repose and Flow of the Particles 
Angle of repose (º) (degrees) Type of flow 
< 25 Excellent 
25-30 Good 
30-40 Passable 
> 40 Very poor 
 
 
Table No.10 
Angle of Repose of Microparticles 
S. No.  Formulation Angle of repose 
1 F1 25º70’ 
2 F2 28º29’ 
3 F3 29º74’ 
4 F4 30º96’ 
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7.4. DRUG ENTRAPMENT EFFICIENCY 
 Drug entrapment efficiency of Esomeprazole Magnesium was performed by 
accurately weighing 100 mg of microparticles and suspend in 100 ml of simulated 
intestinal fluid of pH 7.4±0.1 and it was kept for 12 hrs. Next day it was stirred for 15 
min, and subjected for filtration. After suitable dilution, Esomeprazole magnesium 
content in the filtrate was analyzed Spectrophotometrically at 301 nm using Shimadzu 
1201 UV-visible spectrophotometer. 
 The absorbance found from the UV-Spectrophotometer was plotted on the 
standard curve to get the concentration of the entrapped drug. Calculating this 
concentration with the dilution factor we get the percentage drug encapsulated in 
microparticles. 
 
Table No.11` 
Drug Entrapment Efficiency of Microparticles 
Formulation 
Absorbance at 
301 nm 
Theoretical 
yield (mg) 
Practical yield 
(mg) 
Drug 
Entrapment 
Efficiency 
F1 0.059 50 20.34 79.66 
F2 0.054 50 18.62 81.38 
F3 0.032 50 11.03 88.97 
F4 0.0481 50 16.58 83.42 
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7.5 In-vitro Dissolution Studies 
A drug is expected to release from the solid dosage forms (granules, tablets, capsules etc) 
and immediately go into molecular solution. This process is called as Dissolution. 
Drug release studies 
The method specified in USP for the drug release study was followed. 
Apparatus 
USP XXIII dissolution test apparatus employing the round bottom dissolution vessel and 
rotating basket assembly. 
Buffer stage 
900 ml of pH 7.4 intestinal fluid (phosphate buffer) is used as dissolution media. 
Time 
At every 1 hr interval upto 12 hours. 
Procedure 
In-vitro release profile of the microparticles was evaluated using rotating basket 
dissolution apparatus. 900 ml of phosphate buffer (pH 7.4) maintained at 37±0.5ºC is 
used as dissolution Media, and the basket was rotated at a constant speed of 75 rpm. 
Accurately weighed amount of microparticles were placed in the baskets. 
Aliquots of samples were withdrawn at the interval of 1 hour for 9 hours in phosphate 
buffer pH 7.4. The samples withdrawn were filtered, diluted suitably and analyzed at 301 
nm spectrophotometrically for drug release. 
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Table No. 12 
In-vitro Dissolution Profile for Formulation F1 
 
Graph No 7 
Cumulative % Drug Release Vs Time 
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Cumulative % 
Drug Released 
1 0.08 0.275 9.931 
2 0.12 0.413 14.89 
3 0.18 0.620 22.34 
4 0.22 0.758 27.31 
5 0.25 0.862 31.03 
6 0.29 1.031 36.01 
7 0.35 1.206 43.44 
8 0.43 1.482 53.37 
9 0.57 1.965 70.75 
10 0.65 2.241 80.68 
11 0.71 2.448 88.13 
12 0.75 2.586 93.10 
  Chapter-7                                                                                                               Evaluation Study 
 
Padmavathi College of Pharmacy and Research Institute  68 
 
Table No.13 
In-vitro Dissolution Profile for Formulation F2 
 
Graph No 8 
Cumulative % Drug Release Vs Time 
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Drug Released 
1 0.07 0.214 8.68 
2 0.09 0.310 11.17 
3 0.13 0.448 16.13 
4 0.15 0.517 18.62 
5 0.21 0.724 26.03 
6 0.28 0.965 34.75 
7 0.34 1.172 42.20 
8 0.37 1.275 45.93 
9 0.44 1.517 54.62 
10 0.48 1.655 59.58 
11 0.54 1.862 67.03 
12 0.74 2.551 91.86 
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Table No.14 
In-vitro Dissolution Profile for Formulation F3 
 
Graph No 9 
Cumulative % Drug Release Vs Time 
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Drug Released 
1 0.09 0.31 11.17 
2 0.13 0.044 16.13 
3 0.23 0.724 26.06 
4 0.25 0.852 31.03 
5 0.29 1.068 38.48 
6 0.34 1.172 42.20 
7 0.41 1.413 50.88 
8 0.53 1.827 65.79 
9 0.58 2.006 72.28 
10 0.62 2.137 76.96 
11 0.68 2.379 85.65 
12 0.78 2.689 96.82 
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Table No.15 
In-vitro Dissolution Profile for Formulation F4 
 
Graph No 10 
Cumulative % Drug Release Vs Time 
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Drug Released 
1 0.07 0.241 8.6 
2 0.12 0.413 14.9 
3 0.19 0.655 23.5 
4 0.23 0.793 28.55 
5 0.31 1.068 38.48 
6 0.38 1.310 47.17 
7 0.46 1.586 57.10 
8 0.53 1.827 65.79 
9 0.59 2.034 73.24 
10 0.63 2.172 78.20 
11 0.65 2.241 80.68 
12 0.76 2.620 94.34 
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Table No.16 
 Cumulative % Drug Release Vs Time 
 
 
 
 Cumulative % Drug Release 
Time (hrs) F1 F2 F3 F4 
1 9.931 8.68 11.17 8.6 
2 14.89 11.17 16.13 14.9 
3 22.34 16.13 26.06 23.5 
4 27.31 18.62 31.03 28.55 
5 31.03 26.03 38.48 38.48 
6 36.01 34.75 42.20 47.17 
7 43.44 42.20 50.88 57.10 
8 53.37 45.93 65.79 65.79 
9 70.75 54.62 72.28 73.24 
10 80.68 59.58 76.96 78.20 
11 88.13 67.03 85.65 80.68 
12 93.10 91.86 96.82 94.34 
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Graph No.11 
Percentage Cumulative Percentage Drug Release Vs Time 
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Graph No 12 
Zero Order Release Model Of Formulation F3 
 
 
 
 
 
 
 
 
 
 
Graph No 13 
First order Release Model Of Formulation F3 
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Graph No 14 
Higuchi release model for formulation F3 
 
 
 
 
 
 
 
 
 
 
Graph No 15 
Korsmeyer-Peppas release model for formulation F3 
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Accelarated Stability Studies 
 The formulations were stored in an oven at 37+1oc and 60+1oc for a period of six 
weeks. The samples were analyzed for drug content every week by Spectrophotometer at 
301nm. 
Method 
 Microspheres were individually wrapped in aluminium foil and packed in amber 
colured screw capped bottle and put under specified condition in incubator for 3 months. 
After 3 months the microspheres were evaluated for In-vitro drug release. 
 
Table No.17 
Results of Assay of Formulation After Accelarated Stability Studies 
 
 
Days 37oC 60oC 
1 82.13 81.08 
7 82.08 80.35 
14 81.05 79.01 
21 80.92 78.03 
28 79.87 78.26 
35 77.86 77.22 
42 76.26 76.28 
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RESULTS AND DISCUSSION 
Floating Microspheres of Esomeprazole were prepared by emulsion 
polymerization technique and various evaluation parameters were assessed, with a view 
to obtain oral controlled released of Esomeprazole Magnesium Trihydrate. 
 In the present work, total four formulations were prepared and the detailed 
composition is shown in Table No.5 . The prepared microparticles were then subjected to 
granulometric study, angle of repose, scanning electron microscopy, drug entrapment 
efficiency, in-vitro dissolution and stability studies. 
 A standard calibration curve for the drug was obtained by measuring absorbance 
at 301 nm, and by plotting the graph of absorbance Vs concentration. Table No.4 shows 
the absorbance readings of Esomeprazole. 
 To check the compatibility of the drug with various polymers, IR spectra of drugs, 
polymers and combinations are shown in Graph No.2-6 . The characteristics absorption 
peaks of Esomeprazole magnesium were obtained. 
Angle of Repose 
 Acceptable range of angle of repose is 22º61’ to 31º60’. All the formulations 
showed an angle of repose within the range as shown in Table No.8 . 
 Formulations F1 to F4 showed an angle of repose in the acceptable range, which 
indicates a good flow property. 
The drug entrapment efficiency of all the formulations were in the range between 
78.62 % to 91.25%. The results of drug entrapment efficiency are shown in Table No.9 . 
The dissolution studies were conducted by using dissolution medias, a pH 7.4. 
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 The data obtained in the in-vitro dissolution studies were grouped according to 
modes of data treatment as follows: 
• Cumulative percent drug release Vs. Time (Zero-order). 
• Cumulative percent drug retained Vs. Square root of Time (Higuchi  
Model). 
• Log Cumulative percent drug retained Vs. Time (First-order). 
• Cumulative percent drug release in (mg) Vs. Time (Korsmeyer-Peppas 
Model). 
The results of the in-vitro dissolution studies of formulation F1 to F4 are shown in 
Table No 12-15 . The plots of Cumulative percentage drug release Vs. Time, is drawn 
and represented graphically as shown in Graph No.7 
 Morphology of the microparticles were investigated by Scanning Electron 
Microscopy. The photographs of formulations taken by Scanning Electron Microscope 
are shown in the Figure No.13 and 14 
 Stability study was carried out for the formulation F3 at 40ºC ± 1ºC for a period of 
45 days and the result was shown in Table No.17 
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SUMMARY 
Systematic studies were conducted using two different polymers in different 
concentrations to prepare Esomeprazole Magnesium Trihydrate Floating 
Microspheres. All the prepared systems were evaluated for the different 
properties. 
 
From the Preformulation studies for drug excipients compatibility, it was 
observed that no physical incompatibility existed between the drug and 
excipients. 
 
All the four different formulations prepared contain drug about 97%-102%. 
 
In vitro drug release profile indicated that drug release was retarded due to the 
presence of higher concentration of polymer. 
 
Formulation F2 has only 68%drug release in 9 hrs due to higher ratio of the 
polymer. 
Formulated Microspheres  gave satisfactory results for various evaluation 
parameters like Angle of Repose, Drug Entrapment Efficiency, Scanning 
Electronic Microscopy and in vitro drug release. 
Comparing the two different Polymers such as HPMC and Chitosan provided 
better-sustained release characteristics with excellent  in-vitro drug release. From 
the above results also indicated that at higher viscosity grades of polymer 
concentrations drug release was retarded greatly. 
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CONCLUSION 
Floating  microspheres of Anti-Ulcer drug ie., Esomeprazole Magnesium 
Trihydrate can be formulated as an approach to increase gastric residence time 
and thereby improve its bioavailability. Formulation F3 gave better-controlled 
drug release in comparison to the other formulations. Among the polymers used 
to improve the gastric residence, Chitosan showed better control over drug 
release.  
The drug release pattern from the optimized formulations was best fitted 
to Korsmeyer-Peppas model and zero order kinetics. Drug – excipients interaction 
of optimized formulations was carried out by using FTIR studies. In this analysis 
drug – excipients compatibility interactions were not observed. 
  In conclusion, very promising in vitro drug release results were observed 
with Floating microspheres of Esomeprazole Magnesium Trihydrate, further there 
is a scope to conduct the bioavailability studies in human volunteers to know the 
exact pharmacokinetics of the developed floating microspheres of Esomeprazole 
Magnesium Trihydrate 
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